Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01787305 · ClinicalTrials.gov registry record
Pilot Study of Gut Commensals in Antiphospholipid Syndrome
A clinical trial of Antiphospholipid Syndrome (APS), sponsored by Yale University.
- Active
- Registry status
- 16
- Enrollment target
- 1
- Study location
NCT01787305: Active study of Antiphospholipid Syndrome (APS), sponsored by Yale University.
NCT01787305 is a study of Antiphospholipid Syndrome (APS) that is active but no longer recruiting, run by Yale University. The registered enrollment target is 16 participants. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01787305, a study of Antiphospholipid Syndrome (APS), is active but no longer recruiting, sponsored by Yale University.
- ACTIVE NOT RECRUITING
- Registry status
- 16 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to explore if certain commensals within the gut microbiota (the collection of all microbes that live inside the gut) correlate with autoantibodies in the autoimmune clotting disorder called antiphospholipid syndrome. The study hypothesis is that particular commensals induce the autoantibodies (immune molecules that bind to self structures) and thus correlate with the level of immune cells and antibodies that are self-reactive. Participants are patients with antiphospholipid syndrome and individuals who have tested positive on a prior blood test for anti-beta2-glycoprotein I antibodies or those that have tested negative for antiphospholipid antibodies in their blood, but had a clotting event or a health problem that puts them at risk to form blood clots.
Primary Outcome
Certain gut bacteria will correlate with anti-β2GPI autoantibody titers in anti-β2GPI-positive subjects that are lower or absent in aPL-negative subjects
Conditions Studied
Study Locations (1)
Connecticut
- Yale University School of Medicine; Yale-New Haven Hospital - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2013-02 |
| Est. Completion | 2026-12 |
What the registry record for NCT01787305 still lists
NCT01787305 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 16 participants, a relatively small participant target.
The record links to 1 condition, with Antiphospholipid Syndrome (APS) appearing as the primary indexed condition, and to 0 interventions.
NCT01787305 reports a single indexed study location in Connecticut.
Frequently Asked Questions
What is clinical trial NCT01787305 about?
NCT01787305 is a clinical study titled "Pilot Study of Gut Commensals in Antiphospholipid Syndrome". The purpose of this study is to explore if certain commensals within the gut microbiota (the collection of all microbes that live inside the gut) correlate with autoantibodies in the autoimmune clotting disorder called antiphospholipid syndrome. The study hypothesis is that particular commensals ind...
What is the current status of trial NCT01787305?
This trial is currently active not recruiting. The enrollment target is 16 participants. The study started on 2013-02. Estimated completion is 2026-12.
What conditions does trial NCT01787305 study?
This clinical trial studies the following conditions: Antiphospholipid Syndrome (APS).
Who is sponsoring clinical trial NCT01787305?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01787305 being conducted?
This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Antiphospholipid Syndrome (APS)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02422641 · 16 participants · Phase 2
Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis
- NCT02851758 · 16 participants · NA
Transplantation of Autologously Derived Mitochondria Following Ischemia
- NCT03291028 · 16 participants
Analysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial Carcinoma
- NCT03425526 · 16 participants · Phase 1
Donor T Cell Therapy in Treating Immunocompromised Patients With Adenovirus-Related Disease
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia